From the perspective of treatment, expression of miR-4510 and GPC3 was reversed by oxaliplatin treatment, which significantly reduced the proportion of M2 macrophages and restored the proliferation of CD8+ T cells, suggesting that oxaliplatin may become a specific therapeutic drug in patients with miR-4510 inhibition and GPC3-GC. This evidence concerns the gene CD8A and gastric cancer.